Interfering with interferons in inflammatory bowel disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16849343.
- Also identified by PMC identifier 1856258.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Early experience of fontolizumab, a humanised anti‐interferon γ antibody, in active Crohn's disease has shown that the drug caused a significant decrease in endoscopic severity scores and CRP and was reasonably well tolerated. Fontolizumab may be worthy of further clinical trials
Medical subject headings
- Antibodies, Monoclonal
- Inflammatory Bowel Diseases
- Interferon-gamma